Literature DB >> 18081507

Acute hypobaric hypoxia (5486 m) induces greater pulmonary HIF-1 activation in hilltop compared to madison rats.

Barbara J Engebretsen1, David Irwin, Maria E Valdez, Mary K O'Donovan, Alan Tucker, Martha Tissot van Patot.   

Abstract

Compared to Madison strain Sprague-Dawley rats, the Hilltop strain is resistant to acute hypoxic pulmonary vasoconstriction and pulmonary leak, a pathology resembling high altitude pulmonary edema (HAPE) in humans. Hypoxia inducible transcription factor-1 (HIF-1) mediates transcription of proteins that can "rescue" tissue from hypoxia, including vasoactive and angiogenic proteins such as inducible nitric oxide synthase (iNOS) and vascular endothelial growth factor (VEGF). Because these proteins have theoretical relevance to the etiology of HAPE, we hypothesized that hypoxia-resistant Hilltop rats acutely exposed to high altitude would have greater HIF-1 activity and expression of iNOS and VEGF as compared to hypoxia-sensitive Madison rats. Animals were exposed to normobaric normoxia or hypobaric hypoxia (18 h at 5486 m). The presence of nuclear HIF-1 heterodimer subunits, HIF-1-DNA binding, and iNOS and VEGF protein expression were determined in lung tissue. Hypoxic HIF-1beta expression, HIF-1-DNA binding, and iNOS and VEGF expression were greater in Hilltop than in Madison rats. After 18-h hypobaric hypoxia, HIF-1 activity and HIF-mediated protein expression were elevated in Hilltop rats, but not in Madison rats. To our knowledge, this is the first report of differing HIF-1 activation between two strains of animals with clearly divergent physiological responses to identical hypoxic conditions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18081507     DOI: 10.1089/ham.2007.1031

Source DB:  PubMed          Journal:  High Alt Med Biol        ISSN: 1527-0297            Impact factor:   1.981


  7 in total

Review 1.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

2.  High altitude increases the expression of hypoxia-inducible factor 1α and inducible nitric oxide synthase with intest-inal mucosal barrier failure in rats.

Authors:  Fangxin Zhang; Wenming Wu; Zhiyun Deng; Xiaofeng Zheng; Jiucong Zhang; Shangxin Deng; Jiayu Chen; Qiang Ma; Yong Wang; Xiaohui Yu; Shengchao Kang; Xiufeng Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Hemoglobin-induced endothelial cell permeability is controlled, in part, via a myeloid differentiation primary response gene-88-dependent signaling mechanism.

Authors:  Christina Lisk; Doug Kominsky; Stefan Ehrentraut; Joe Bonaventura; Rachelle Nuss; Kathryn Hassell; Eva Nozik-Grayck; David C Irwin
Journal:  Am J Respir Cell Mol Biol       Date:  2013-10       Impact factor: 6.914

4.  Rat strain differences in pulmonary artery smooth muscle Ca(2+) entry following chronic hypoxia.

Authors:  Jessica B Snow; Nancy L Kanagy; Benjimen R Walker; Thomas C Resta
Journal:  Microcirculation       Date:  2009-07-22       Impact factor: 2.628

5.  Placenta growth factor and vascular endothelial growth factor B expression in the hypoxic lung.

Authors:  Michelle Sands; Katherine Howell; Christine M Costello; Paul McLoughlin
Journal:  Respir Res       Date:  2011-01-25

6.  New insights of aquaporin 5 in the pathogenesis of high altitude pulmonary edema.

Authors:  Jun She; Jing Bi; Lin Tong; Yuanlin Song; Chunxue Bai
Journal:  Diagn Pathol       Date:  2013-11-25       Impact factor: 2.644

7.  Expression of Aquaporin-1 and Aquaporin-5 in a Rat Model of High-Altitude Pulmonary Edema and the Effect of Hyperbaric Oxygen Exposure.

Authors:  Jiewen Tan; Chunjin Gao; Cong Wang; Linlin Ma; Xiaomin Hou; Xuehua Liu; Zhuo Li
Journal:  Dose Response       Date:  2020-10-30       Impact factor: 2.658

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.